Photoreceptor degeneration in ABCA4-associated retinopathy and its genetic correlates.


Journal

JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073

Informations de publication

Date de publication:
25 01 2022
Historique:
received: 28 09 2021
accepted: 01 12 2021
entrez: 25 1 2022
pubmed: 26 1 2022
medline: 23 3 2022
Statut: epublish

Résumé

BACKGROUNDOutcome measures sensitive to disease progression are needed for ATP-binding cassette, sub-family A, member 4-associated (ABCA4-associated) retinopathy. We aimed to quantify ellipsoid zone (EZ) loss and photoreceptor degeneration beyond EZ-loss in ABCA4-associated retinopathy and investigate associations between photoreceptor degeneration, genotype, and age.METHODSWe analyzed 132 eyes from 66 patients (of 67 enrolled) with molecularly confirmed ABCA4-associated retinopathy from a prospective natural history study with a median [IQR] follow-up of 4.2 years [3.1, 5.1]. Longitudinal spectral-domain optical coherence tomography volume scans (37 B-scans, 30° × 15°) were segmented using a deep learning (DL) approach. For genotype-phenotype analysis, a model of ABCA4 variants was applied with the age of criterion EZ-loss (6.25 mm2) as the dependent variable.RESULTSPatients exhibited an average (square-root-transformed) EZ-loss progression rate of [95% CI] 0.09 mm/y [0.06, 0.11]. Outer nuclear layer (ONL) thinning extended beyond the area of EZ-loss. The average distance from the EZ-loss boundary to normalization of ONL thickness (to ±2 z score units) was 3.20° [2.53, 3.87]. Inner segment (IS) and outer segment (OS) thinning was less pronounced, with an average distance from the EZ-loss boundary to layer thickness normalization of 1.20° [0.91, 1.48] for the IS and 0.60° [0.49, 0.72] for the OS. An additive model of allele severity explained 52.7% of variability in the age of criterion EZ-loss.CONCLUSIONPatients with ABCA4-associated retinopathy exhibited significant alterations of photoreceptors outside of EZ-loss. DL-based analysis of photoreceptor laminae may help monitor disease progression and estimate the severity of ABCA4 variants.TRIAL REGISTRATIONClinicalTrials.gov identifier: NCT01736293.FUNDINGNational Eye Institute Intramural Research Program and German Research Foundation grant PF950/1-1.

Identifiants

pubmed: 35076026
pii: 155373
doi: 10.1172/jci.insight.155373
pmc: PMC8855828
doi:
pii:

Substances chimiques

ABCA4 protein, human 0
ATP-Binding Cassette Transporters 0

Banques de données

ClinicalTrials.gov
['NCT01736293']

Types de publication

Journal Article Observational Study Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Mol Ther Nucleic Acids. 2020 Sep 4;21:412-427
pubmed: 32653833
Retina. 2021 Dec 1;41(12):2578-2588
pubmed: 34125082
Sci Rep. 2021 Jan 14;11(1):1466
pubmed: 33446864
Hum Mol Genet. 2004 Mar 1;13(5):525-34
pubmed: 14709597
Genome Res. 2018 Jan;28(1):100-110
pubmed: 29162642
Ophthalmology. 2016 Jun;123(6):1375-85
pubmed: 26976702
Invest Ophthalmol Vis Sci. 2000 Sep;41(10):3200-9
pubmed: 10967084
Invest Ophthalmol Vis Sci. 2016 Dec 1;57(15):6824-6830
pubmed: 28002570
Hum Mol Genet. 2021 Jun 26;30(14):1293-1304
pubmed: 33909047
Eye (Lond). 2019 Nov;33(11):1683-1698
pubmed: 31164730
JAMA Ophthalmol. 2017 Nov 1;135(11):1232-1241
pubmed: 29049437
Nat Genet. 1997 Mar;15(3):236-46
pubmed: 9054934
Graefes Arch Clin Exp Ophthalmol. 2019 Mar;257(3):549-556
pubmed: 30613916
JAMA Ophthalmol. 2020 Oct 1;138(10):1035-1042
pubmed: 32815999
Am J Ophthalmol. 2021 Feb;222:340-350
pubmed: 32891696
Invest Ophthalmol Vis Sci. 2018 Mar 20;59(4):AMD122-AMD131
pubmed: 30140905
Invest Ophthalmol Vis Sci. 2020 Apr 9;61(4):36
pubmed: 32334431
Invest Ophthalmol Vis Sci. 2019 Sep 3;60(12):3992-4001
pubmed: 31560765
Sci Rep. 2020 Oct 6;10(1):16576
pubmed: 33024232
Am J Ophthalmol. 2018 Feb;186:1-9
pubmed: 29126757
Genet Med. 2020 Jul;22(7):1235-1246
pubmed: 32307445
Invest Ophthalmol Vis Sci. 2013 Apr 17;54(4):2812-20
pubmed: 23548623
JAMA Ophthalmol. 2019 Oct 1;137(10):1134-1145
pubmed: 31369039
J Clin Med. 2020 Jul 29;9(8):
pubmed: 32751377
JAMA Ophthalmol. 2013 Sep;131(9):1143-50
pubmed: 23828615
Transl Vis Sci Technol. 2019 Mar 1;8(2):1
pubmed: 30834176
Am J Ophthalmol. 2013 Jun;155(6):1075-1088.e13
pubmed: 23499370
Retina. 2020 Dec;40(12):2343-2356
pubmed: 33214501
Ophthalmology. 2019 Sep;126(9):1288-1296
pubmed: 31227323
Ophthalmology. 2015 Feb;122(2):335-44
pubmed: 25444351
Hum Mol Genet. 2015 Jun 1;24(11):3220-37
pubmed: 25712131
Transl Vis Sci Technol. 2018 Oct 1;7(5):13
pubmed: 30279998
Hum Mol Genet. 2009 Mar 1;18(5):931-41
pubmed: 19074458
Invest Ophthalmol Vis Sci. 2009 Dec;50(12):5867-71
pubmed: 19578016
Invest Ophthalmol Vis Sci. 2015 Sep;56(10):5946-55
pubmed: 26377081
JAMA Ophthalmol. 2013 Jan;131(1):110-1
pubmed: 23307222
Invest Ophthalmol Vis Sci. 2005 Dec;46(12):4739-46
pubmed: 16303974
Invest Ophthalmol Vis Sci. 2016 Oct 1;57(13):5186-5191
pubmed: 27699414
Am J Hum Genet. 1999 Feb;64(2):422-34
pubmed: 9973280
Invest Ophthalmol Vis Sci. 2012 Sep 14;53(10):6145-52
pubmed: 22899757
Invest Ophthalmol Vis Sci. 2014 May 01;55(5):2841-52
pubmed: 24677105
JAMA Ophthalmol. 2020 Oct 1;138(10):1026-1034
pubmed: 32789526
Curr Eye Res. 2015 Apr;40(4):398-406
pubmed: 24912073
Invest Ophthalmol Vis Sci. 2016 Nov 1;57(14):5963-5973
pubmed: 27820952

Auteurs

Maximilian Pfau (M)

National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA.
Department of Ophthalmology, University of Bonn, Bonn, Germany.

Catherine A Cukras (CA)

National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA.

Laryssa A Huryn (LA)

National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA.

Wadih M Zein (WM)

National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA.

Ehsan Ullah (E)

National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA.

Marisa P Boyle (MP)

National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA.

Amy Turriff (A)

National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA.

Michelle A Chen (MA)

National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA.

Aarti S Hinduja (AS)

National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA.

Hermann Ea Siebel (HE)

National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA.

Robert B Hufnagel (RB)

National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA.

Brett G Jeffrey (BG)

National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA.

Brian P Brooks (BP)

National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH